Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

Table 2 DLTs according to dose levels

Dose level	Number of Assessable patients	Bevacizumab (Q2W)	Pazopanib (Q.D)	Number of DLT
DL1	9	7.5 mg/kg	400 mg	No DLT
DL1 Confirmatory Cohort	6			3 DLT:- 2 grade 3 MAHA^b
DL1 Confirmatory Cohort	6			- 1 grade 3 ALT/AST
DL2	10^a	7.5 mg/kg	600 mg	5 DLT:- 2 grade 3 ALT/AST^c
				- 1 grade 3 pulmonary embolism^c
				- 2 grade 3 MAHA^c

ISSN: 1471-2407